Expression of c-FLIP in pulmonary metastases in osteosarcoma patients and human xenografts

Pediatric Blood and Cancer

Volumn 60, Issue 4, 2013, Pages 575-579

  Rao Bindal, Krithi ^a   Rao, Chethan K ^a   Yu, Ling ^a   Kleinerman, Eugenie S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

C FLIP; Fas FasL pathway; Osteosarcoma; Pulmonary metastasis

Indexed keywords

FLICE INHIBITORY PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURGERY; CASE REPORT; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS EPITHELIUM; LUNG METASTASIS; LUNG RESECTION; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIMARY TUMOR; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

ADOLESCENT; ANIMALS; BONE NEOPLASMS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; OSTEOSARCOMA; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84873723103     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24412     Document Type: Article

References (30)

1. Kaste S, Pratt C, Cain A, et al. Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: Imaging features. Cancer 1999; 86: 1602-1608.
2. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004; 10: 182-186.
3. Wang LL. Biology of osteogenic sarcoma. Cancer J 2005; 11: 294-305.
4. Gillette J, Chan D, Nielsen-Preiss S. Annexin 2 expression is reduced in human osteosarcoma metastases. J Cell Biochem 2004; 92: 820-832.
5. Perissinotto E, Cavalloni G, Leone F, et al. Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res 2005; 11: 490-497.
6. Koshkina NV, Khanna C, Mendoza A, et al. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: The role of the fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res 2007; 5: 991-999.
7. Gordon N, Kleinerman ES. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases. Cancer Treat Res 2009; 152: 497-508.
8. Wajant H. The fas signaling pathway: More than a paradigm. Science 2002; 296: 1635-1636.
9. Worth LL, Lafleur EA, Jia SF, et al. Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep 2002; 9: 823-827.
10. Gordon N, Arndt CA, Hawkins DS, et al. Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 2005; 27: 611-615.
11. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190-195.
12. Korkolopoulou P, Goudopoulou A, Voutsinas G, et al. c-FLIP expression in bladder urothelial carcinomas: Its role in resistance to fas-mediated apoptosis and clinicopathologic correlations. Urology 2004; 63: 1198-1204.
13. Valente G, Manfroi F, Peracchio C, et al. C-FLIP expression correlates with tumour progression and patient outcome in non-hodgkin lymphomas of low grade of malignancy. Br J Haematol 2006; 132: 560-570.
14. Ryu BK, Lee MG, Chi SG, et al. Increased expression of c-FLIP(l) in colonic adenocarcinoma. J Pathol 2001; 194: 15-19.
15. Longley DB, Wilson TR, McEwan M, et al. C-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 2006; 25: 838-848.
16. Matta H, Eby MT, Gazdar AF, et al. Role of mrit/cflip in protection against chemotherapy-induced apoptosis. Cancer Biol Ther 2002; 1: 652-660.
17. Hughes DP. Strategies for the targeted delivery of therapeutics for osteosarcoma. Expert Opin Drug Deliv 2009; 6: 1311-1321.
18. Lee SH, Kim HS, Kim SY, et al. Increased expression of flip, an inhibitor of fas-mediated apoptosis, in stomach cancer. APMIS 2003; 111: 309-314.
19. Korkolopoulou P, Lazaris A, Konstantinidou AE, et al. Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival. Eur Urol 2002; 41: 274-283.
20. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of iap-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000; 6: 1796-1803.
21. Korkolopoulou P, Saetta AA, Levidou G, et al. C-flip expression in colorectal carcinomas: Association with Fas/FasL expression and prognostic implications. Histopathology 2007; 51: 150-156.
22. Ryang DY, Joo YE, Chung KM, et al. Expression of c-flip in gastric cancer and its relation to tumor cell proliferation and apoptosis. Korean J Intern Med 2007; 22: 263-269.
23. Li Z, Xu X, Bai L, et al. Epidermal growth factor receptor-mediated tissue transglutaminase overexpression couples acquired tumor necrosis factor-related apoptosis-inducing ligand resistance and migration through c-flip and mmp-9 proteins in lung cancer cells. J Biol Chem 2011; 286: 21164-21172.
24. Galligan L, Longley DB, McEwan M, et al. Chemotherapy and trail-mediated colon cancer cell death: The roles of p53, trail receptors, and c-flip. Mol Cancer Ther 2005; 4: 2026-2036.
25. Rao-Bindal K, Kleinerman ES. The histone deacetylase inhibitor, MS-275, sensitizes osteosarcoma cells and osteosarcoma lung metastases to FasL-induced cell death by the downregulation c-FLIP [abstract]. Orlando. Florida: Philadelphia (PA): AACR; 2011; April 2-5.
26. Rao-Bindal K, Zhou Z, Kleinerman ES. MS-275 senstizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts. Cell Death Dis 2012; 3: e369.
27. Ahn EY, Pan G, Vickers SM, et al. IFN-gamma upregulates apoptosis-related molecules and enhances Fas-mediated apoptosis in human cholangiocarcinoma. Int J Cancer 2002; 100: 445-451.
28. Kanetaka Y, Hayashida M, Hoshika A, et al. Interferon-alpha induces transient upregulation of c-FLIP through NF-kappa B activation. Exp Cell Res 2008; 314: 246-254.
29. Budd RC, Yeh WC, Tschopp J. cFLIP regulation of lymphocyte activation and development. Nat Rev Immunol 2006; 6: 196-204.
30. Kothny-Wilkes G, Kulms D, Pöppelmann B, et al. Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 1998; 273: 29247-29253.